These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25505041)

  • 1. Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.
    Matthews PE; Le T; Delmar J; Okulicz JF
    Int J STD AIDS; 2015 Nov; 26(13):951-9. PubMed ID: 25505041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic.
    Purkayastha T; Wasi F; Shuter J
    AIDS Patient Care STDS; 2005 Dec; 19(12):785-93. PubMed ID: 16375610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linkage and retention in care and the time to HIV viral suppression and viral rebound - New York City.
    Robertson M; Laraque F; Mavronicolas H; Braunstein S; Torian L
    AIDS Care; 2015; 27(2):260-7. PubMed ID: 25244545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance.
    Weidle PJ; Malamba S; Mwebaze R; Sozi C; Rukundo G; Downing R; Hanson D; Ochola D; Mugyenyi P; Mermin J; Samb B; Lackritz E
    Lancet; 2002 Jul; 360(9326):34-40. PubMed ID: 12114039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.